A new study shows that food insecurity in pregnant women being treated for opioid use disorder may be associated with increased risk for their infants receiving pharmacologic treatment for neonatal abstinence syndrome. Published in Addiction, the Boston Medical Center study indicates that screening for food insecurity in pregnant women who are being treated with opioid agonist therapy (methadone or buprenorphine) for an opioid use disorder could be one way to decrease the severity of neonatal abstinence syndrome in their infants.
Neonatal abstinence syndrome (NAS) is an opioid withdrawal syndrome that occurs after in-utero opioid exposure. Approximately 50 to 80 percent of infants exposed to methadone or buprenorphine in-utero are treated pharmacologically for NAS, with an average length of hospitalization of 23 days nationally when medication is required. In addition, it is well documented that food insecurity during pregnancy in the general population is associated with negative maternal and child outcomes including gestational diabetes for the mother, and developmental risk and chronic disease for the child.
The prospective cohort study included 75 pregnant women attending an integrated prenatal care and addiction treatment program for opioid use disorder at an urban academic medical center. The women were interviewed during the third trimester about their demographics, food insecurity and depression. After birth, the infants were managed with the hospital standard of care including rooming-in with their mothers and monitoring for NAS with pharmacological treatment per hospital guidelines. Breastfeeding was encouraged in women who were stable on their opioid agonist medication.
More than 57 percent of the mothers included in the study reported that they experienced food insecurity during pregnancy. Additional analyses showed that there was a three to four-fold increase in receipt of pharmacologic treatment for NAS for infants whose mothers were food insecure versus food secure.
"To our knowledge, this study is the first to examine whether there is a relationship between food insecurity in pregnant women receiving opioid agonist treatment and increased risk for the infant to receive pharmacological treatment for NAS severity," said lead author Ruth Rose-Jacobs, ScD, from the department of pediatrics at both BMC and Boston University School of Medicine. "While the mechanisms behind variation in NAS severity is complex and not well understood, screening tools and interventions for food insecurity are known and available."
The authors note that screening for food insecurity and providing food security interventions within comprehensive prenatal treatment for women with opioid use disorders and as an adjunct to other NAS interventions might decrease NAS severity and improve long-term infant and mother outcomes."
This study was funded in part by the Administration for Children and Families, a division of the US Department of Health and Human Services.
About Boston Medical Center
Boston Medical Center is a private, not-for-profit, 487-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $116 million in sponsored research funding in fiscal year 2017. It is the 15th largest recipient of funding in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet - 14 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.